Skip to main content

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy DeuterOncology obtains SPW grant funding Liège, Belgium, April 07, 2023 – DeuterOncology, a Liège-Based (BE) biotech company, is pleased to announce it has successfully been awarded the Win4Company grant by the Wallonie recherche SPW. The clinical-stage drug...
Read More

Mark your calendars for BioWin Day: empowering health

BioWin Day: empowering health is the premier event for professionals and decision-makers in the life sciences industry, including biotech, (bio)pharma, medtech, and e-health. As the 8th edition of this biennial event, it serves as a platform for regional and international stakeholders to exchange knowledge, inspire innovation, and drive economic growth....
Read More

ImmuneWatch, Quantoom Biosciences (Univercells) and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines

March 30, 2023 Quantoom Biosciences (“Quantoom”), ImmuneWatch and UAntwerp (Lab of Experimental Hematology) are delighted to announce a public-private partnership in a project under the “Pandemic Preparedness” call, launched by the University of Antwerp in 2022. “The goal of this project is to assess if a detailed analysis of the...
Read More

Quantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry (Région Île-de-France)

Brussels (Belgium) – March 2, 2023 Quantoom Biosciences S.A. (“Quantoom”), a Belgian biotech with the mission to reinvent mRNA production announces today the opening of a brand-new facility in Évry-Courcouronnes (France). Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but these…

Read More

ABSCINT and the VUB announce a Notice of Allowance for their U.S. Patent covering diagnostic applications of its single-domain antibody labelled with radioisotopes for PET/CT imaging of HER2 cancer lesions

  Brussels, Liège, February 20, 2023. Vrije Universiteit Brussel (VUB) and its spin-off ABSCINT announce today that the United States Patent and Trademark Office (“USPTO”) has provided a Notice of Allowance for patent application No. 16/827,032, entitled “Radio-labelled antibody fragments for use in the prognosis and diagnosis of cancer as well as for the…

Read More